diffuse large B-cell lymphoma
Conditions
Interventions
study group:Glofitamab plus Gemox
Sponsors
The first affiliated hospital Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) According to the fifth edition of WHO Classification of lymphohematopoietic tumors, the patient was pathologically diagnosed as diffuse large B-cell lymphoma; 2) Age 18-65; 3) ECOG score: 0-2 4) After 2-4 courses of first-line anti-DLBCL regimen, PET-CT was evaluated as PD and SD; 5) PET-CT or CT/MRI shows at least one two-dimensional measurable lesion (maximum diameter > 1.5cm) 6) women of childbearing age must be confirmed by pregnancy test not pregnant, and are willing to take effective contraceptive measures during the test period and =12 months after the last dose; Pregnant and lactating women cannot participate; All male subjects used contraception during the study period and =3 months after the last dose; 7) Can provide informed consent, can understand and comply with the study requirements.
Exclusion criteria
Exclusion criteria: 1) Severe mental illness 2) HIV infection 3) previous regimen contain Glofitamab or Gemox
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall respond rate;Progression-free survival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The first affiliated hospital Zhejiang University school of medicine
Outcome results
None listed